Equities Analysts Issue Forecasts for ASMB FY2029 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Assembly Biosciences in a research note issued to investors on Monday, March 24th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will post earnings per share of ($12.58) for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The firm had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.05 million.

Separately, StockNews.com lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Monday.

Assembly Biosciences Trading Up 1.0 %

Shares of NASDAQ ASMB opened at $11.12 on Tuesday. The stock has a market cap of $70.68 million, a P/E ratio of -1.65 and a beta of 0.62. The business’s fifty day simple moving average is $12.84 and its 200-day simple moving average is $15.09. Assembly Biosciences has a 12-month low of $10.27 and a 12-month high of $19.93.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC lifted its position in shares of Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 3,635 shares during the period. JPMorgan Chase & Co. raised its holdings in Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 3,442 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in Assembly Biosciences during the fourth quarter worth $994,000. Palumbo Wealth Management LLC acquired a new stake in Assembly Biosciences in the fourth quarter valued at $180,000. Finally, Monimus Capital Management LP purchased a new position in shares of Assembly Biosciences in the fourth quarter valued at $664,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Assembly Biosciences news, Director Michael Houghton bought 3,202 shares of the firm’s stock in a transaction dated Monday, December 30th. The stock was acquired at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the purchase, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.10% of the stock is owned by company insiders.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.